Literature DB >> 35105981

Innate immunity: the first line of defense against SARS-CoV-2.

Michael S Diamond1,2,3,4, Thirumala-Devi Kanneganti5.   

Abstract

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus (SARS-CoV)-2, continues to cause substantial morbidity and mortality. While most infections are mild, some patients experience severe and potentially fatal systemic inflammation, tissue damage, cytokine storm and acute respiratory distress syndrome. The innate immune system acts as the first line of defense, sensing the virus through pattern recognition receptors and activating inflammatory pathways that promote viral clearance. Here, we discuss innate immune processes involved in SARS-CoV-2 recognition and the resultant inflammation. Improved understanding of how the innate immune system detects and responds to SARS-CoV-2 will help identify targeted therapeutic modalities that mitigate severe disease and improve patient outcomes.
© 2022. Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35105981      PMCID: PMC8935980          DOI: 10.1038/s41590-021-01091-0

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   31.250


  149 in total

1.  Rapid COVID-19 vaccine development.

Authors:  Barney S Graham
Journal:  Science       Date:  2020-05-08       Impact factor: 47.728

2.  Intracellular innate immune receptors: Life inside the cell.

Authors:  Thirumala-Devi Kanneganti
Journal:  Immunol Rev       Date:  2020-09       Impact factor: 12.988

3.  Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis.

Authors:  Adam Booth; Angus Bruno Reed; Sonia Ponzo; Arrash Yassaee; Mert Aral; David Plans; Alain Labrique; Diwakar Mohan
Journal:  PLoS One       Date:  2021-03-04       Impact factor: 3.240

Review 4.  The 'cytokine storm': molecular mechanisms and therapeutic prospects.

Authors:  Rajendra Karki; Thirumala-Devi Kanneganti
Journal:  Trends Immunol       Date:  2021-07-01       Impact factor: 19.709

5.  The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway.

Authors:  Jin-Yan Li; Ce-Heng Liao; Qiong Wang; Yong-Jun Tan; Rui Luo; Ye Qiu; Xing-Yi Ge
Journal:  Virus Res       Date:  2020-06-23       Impact factor: 3.303

6.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

7.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

8.  SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant.

Authors:  Yoriyuki Konno; Izumi Kimura; Keiya Uriu; Masaya Fukushi; Takashi Irie; Yoshio Koyanagi; Daniel Sauter; Robert J Gifford; So Nakagawa; Kei Sato
Journal:  Cell Rep       Date:  2020-09-04       Impact factor: 9.423

Review 9.  COVID-19 vaccine challenges: What have we learned so far and what remains to be done?

Authors:  Rebecca Forman; Soleil Shah; Patrick Jeurissen; Mark Jit; Elias Mossialos
Journal:  Health Policy       Date:  2021-03-26       Impact factor: 3.255

10.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.

Authors:  Daniel Blanco-Melo; Benjamin E Nilsson-Payant; Wen-Chun Liu; Skyler Uhl; Daisy Hoagland; Rasmus Møller; Tristan X Jordan; Kohei Oishi; Maryline Panis; David Sachs; Taia T Wang; Robert E Schwartz; Jean K Lim; Randy A Albrecht; Benjamin R tenOever
Journal:  Cell       Date:  2020-05-15       Impact factor: 41.582

View more
  46 in total

Review 1.  Immune responses to SARS-CoV-2 in dialysis and kidney transplantation.

Authors:  Chiara Cantarelli; Andrea Angeletti; Laura Perin; Luis Sanchez Russo; Gianmarco Sabiu; Manuel Alfredo Podestà; Paolo Cravedi
Journal:  Clin Kidney J       Date:  2022-07-27

2.  New Insights into Clinical and Mechanistic Heterogeneity of the Acute Respiratory Distress Syndrome: Summary of the Aspen Lung Conference 2021.

Authors:  Thomas R Martin; Rachel L Zemans; Lorraine B Ware; Eric P Schmidt; David W H Riches; Lisa Bastarache; Carolyn S Calfee; Tushar J Desai; Susanne Herold; Catherine L Hough; Mark R Looney; Michael A Matthay; Nuala Meyer; Samir M Parikh; Troy Stevens; B Taylor Thompson
Journal:  Am J Respir Cell Mol Biol       Date:  2022-09       Impact factor: 7.748

3.  Serum gasdermin D levels are associated with the chest computed tomography findings and severity of COVID-19.

Authors:  Shotaro Suzuki; Mitsuru Imamura; Mariko Mouri; Tomoya Tsuchida; Hayato Tomita; Shin Matsuoka; Mumon Takita; Kazutaka Kakinuma; Tatsuya Kawasaki; Keiichi Sakurai; Kazuko Yamazaki; Manae S Kurokawa; Hiroyuki Kunishima; Takahide Matsuda; Masamichi Mineshita; Hiromu Takemura; Shigeki Fujitani; Seido Ooka; Takahiko Sugihara; Tomohiro Kato; Kimito Kawahata
Journal:  Respir Investig       Date:  2022-07-12

Review 4.  Innate and Adaptive Immune Responses in the Upper Respiratory Tract and the Infectivity of SARS-CoV-2.

Authors:  Ranjan Ramasamy
Journal:  Viruses       Date:  2022-04-29       Impact factor: 5.818

Review 5.  Host-directed immunotherapy of viral and bacterial infections: past, present and future.

Authors:  Robert S Wallis; Anne O'Garra; Alan Sher; Andreas Wack
Journal:  Nat Rev Immunol       Date:  2022-06-07       Impact factor: 108.555

Review 6.  Pathogenic Mechanism and Multi-omics Analysis of Oral Manifestations in COVID-19.

Authors:  Ming Hao; Dongxu Wang; Qianyun Xia; Shaoning Kan; Lu Chang; Huimin Liu; Zhijing Yang; Weiwei Liu
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

7.  Modeling recapitulates the heterogeneous outcomes of SARS-CoV-2 infection and quantifies the differences in the innate immune and CD8 T-cell responses between patients experiencing mild and severe symptoms.

Authors:  Budhaditya Chatterjee; Harshbir Singh Sandhu; Narendra M Dixit
Journal:  PLoS Pathog       Date:  2022-06-27       Impact factor: 7.464

Review 8.  Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors.

Authors:  Roberta Rovito; Matteo Augello; Assaf Ben-Haim; Valeria Bono; Antonella d'Arminio Monforte; Giulia Marchetti
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

Review 9.  Illustrated State-of-the-Art Capsules of the ISTH 2022 Congress.

Authors:  Robert A Ariëns; Beverley J Hunt; Ejaife O Agbani; Josefin Ahnström; Robert Ahrends; Raza Alikhan; Alice Assinger; Zsuzsa Bagoly; Alessandra Balduini; Elena Barbon; Christopher D Barrett; Paul Batty; Jorge David Aivazoglou Carneiro; Wee Shian Chan; Moniek de Maat; Kerstin de Wit; Cécile Denis; Martin H Ellis; Renee Eslick; Hongxia Fu; Catherine P M Hayward; Benoit Ho-Tin-Noé; Frederikus A Klok; Riten Kumar; Karin Leiderman; Rustem I Litvinov; Nigel Mackman; Zoe McQuilten; Matthew D Neal; William A E Parker; Roger J S Preston; Julie Rayes; Alireza R Rezaie; Lara N Roberts; Bianca Rocca; Susan Shapiro; Deborah M Siegal; Lirlândia P Sousa; Katsue Suzuki-Inoue; Tahira Zafar; Jiaxi Zhou
Journal:  Res Pract Thromb Haemost       Date:  2022-07-06

Review 10.  Surviving the Storm: Cytokine Biosignature in SARS-CoV-2 Severity Prediction.

Authors:  Rahnuma Ahmad; Mainul Haque
Journal:  Vaccines (Basel)       Date:  2022-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.